Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 322

1.

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.

Gershenson DM, Sun CC, Lu KH, Coleman RL, Sood AK, Malpica A, Deavers MT, Silva EG, Bodurka DC.

Obstet Gynecol. 2006 Aug;108(2):361-8.

PMID:
16880307
2.

Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.

Gadducci A, Landoni F, Sartori E, Maggino T, Zola P, Gabriele A, Rossi R, Cosio S, Fanucchi A, Tisi G.

Gynecol Oncol. 2001 May;81(2):150-9.

PMID:
11330942
3.

Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.

Schmeler KM, Sun CC, Bodurka DC, Deavers MT, Malpica A, Coleman RL, Ramirez PT, Gershenson DM.

Gynecol Oncol. 2008 Mar;108(3):510-4. Epub 2007 Dec 26.

PMID:
18155273
4.

Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma.

Sood BM, Jones J, Gupta S, Khabele D, Guha C, Runowicz C, Goldberg G, Fields A, Anderson P, Vikram B.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):208-16.

PMID:
12909235
5.

Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.

Randall ME, Barrett RJ, Spirtos NM, Chalas E, Homesley HD, Lentz SL, Hanna M.

Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):139-47.

PMID:
12118543
6.

Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).

Goldberg H, Miller RC, Abdah-Bortnyak R, Steiner M, Yildiz F, Meirovitz A, VillĂ  S, Poortmans PM, Azria D, Zidan J, Ozsahin M, Abacioglu U, Gold DG, Amit A, Lavie O, Atahan IL, Kuten A; Rare Cancer Network.

Gynecol Oncol. 2008 Feb;108(2):298-305. Epub 2007 Dec 21.

PMID:
18096209
7.

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.

Shvartsman HS, Sun CC, Bodurka DC, Mahajan V, Crispens M, Lu KH, Deavers MT, Malpica A, Silva EG, Gershenson DM.

Gynecol Oncol. 2007 Jun;105(3):625-9. Epub 2007 Feb 22.

PMID:
17320156
8.

Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a Gynecologic Oncology Group Study.

Bloss JD, Brady MF, Liao SY, Rocereto T, Partridge EE, Clarke-Pearson DL; Gynecologic Oncology Group Study.

Gynecol Oncol. 2003 Apr;89(1):148-54.

PMID:
12694669
9.

Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.

Landrum LM, Moore KN, Myers TK, Lanneau GS Jr, McMeekin DS, Walker JL, Gold MA.

Gynecol Oncol. 2009 Feb;112(2):337-41. doi: 10.1016/j.ygyno.2008.10.009. Epub 2008 Nov 28.

PMID:
19041126
10.

The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.

Bristow RE, Duska LR, Montz FJ.

Gynecol Oncol. 2001 Apr;81(1):92-9.

PMID:
11277657
11.

[Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III-IV ovarian papillary serous carcinoma].

Gao YN, Liu JX, Wang W, Li WF, Tang WS.

Zhonghua Zhong Liu Za Zhi. 2005 Mar;27(3):171-3. Chinese.

PMID:
15946570
12.

High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.

Stiff PJ, Bayer R, Kerger C, Potkul RK, Malhotra D, Peace DJ, Smith D, Fisher SG.

J Clin Oncol. 1997 Apr;15(4):1309-17.

PMID:
9193322
13.

The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.

Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS.

Gynecol Oncol. 2002 May;85(2):351-5.

PMID:
11972399
14.

Extended surgical staging for uterine papillary serous carcinoma: survival outcome of locoregional (Stage I-III) disease.

Bristow RE, Asrari F, Trimble EL, Montz FJ.

Gynecol Oncol. 2001 May;81(2):279-86.

PMID:
11330963
15.

CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.

Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, Abu-Rustum NR, Poynor EA, Aghajanian C, Spriggs D, Hensley ML, Sabbatini P.

Gynecol Oncol. 2007 Jan;104(1):176-80. Epub 2006 Sep 25.

PMID:
16996584
16.

Micropapillary serous ovarian carcinoma: surgical management and clinical outcome.

Bristow RE, Gossett DR, Shook DR, Zahurak ML, Tomacruz RS, Armstrong DK, Montz FJ.

Gynecol Oncol. 2002 Aug;86(2):163-70.

PMID:
12144823
17.

Micropapillary and cribriform patterns in ovarian serous tumors of low malignant potential: a study of 99 advanced stage cases.

Deavers MT, Gershenson DM, Tortolero-Luna G, Malpica A, Lu KH, Silva EG.

Am J Surg Pathol. 2002 Sep;26(9):1129-41.

PMID:
12218569
18.

Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival.

Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ.

Gynecol Oncol. 2000 Aug;78(2):85-91.

PMID:
10926785
19.

Serous ovarian tumors of low malignant potential with peritoneal implants.

Gershenson DM, Silva EG.

Cancer. 1990 Feb 1;65(3):578-85.

20.

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.

Gershenson DM, Sun CC, Bodurka D, Coleman RL, Lu KH, Sood AK, Deavers M, Malpica AL, Kavanagh JJ.

Gynecol Oncol. 2009 Jul;114(1):48-52. doi: 10.1016/j.ygyno.2009.03.001. Epub 2009 Apr 10.

PMID:
19361839
Items per page

Supplemental Content

Write to the Help Desk